Brown, Lisle/Cummings’s ResMed RMD Stock Holding History

Brown, Lisle/Cummings’s Portfolio RMD Stock Details RMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$62K	Buy	276 +6	+2%	+$1.5K	0.02%	325
2025 Q4	$65K	Hold	270	–	–	0.02%	317
2025 Q3	$73.9K	Hold	270	–	–	0.02%	301
2025 Q2	$69.7K	Hold	270	–	–	0.02%	302
2025 Q1	$60.4K	Hold	270	–	–	0.02%	311
2024 Q4	$61.7K	Hold	270	–	–	0.02%	307
2024 Q3	$65.9K	Hold	270	–	–	0.02%	295
2024 Q2	$51.7K	Hold	270	–	–	0.02%	307
2024 Q1	$53.5K	Hold	270	–	–	0.02%	284
2023 Q4	$46.4K	Hold	270	–	–	0.02%	294
2023 Q3	$39.9K	Hold	270	–	–	0.02%	281
2023 Q2	$59K	Hold	270	–	–	0.03%	263
2023 Q1	$59.1K	Hold	270	–	–	0.03%	263
2022 Q4	$56.2K	Hold	270	–	–	0.03%	253
2022 Q3	$58.9K	Hold	270	–	–	0.03%	243
2022 Q2	$56.6K	Hold	270	–	–	0.03%	246
2022 Q1	$65.5K	Hold	270	–	–	0.03%	242
2021 Q4	$70.3K	Buy	+270	New	+$70.1K	0.04%	237

Other funds holding RMD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

DAM

Diamant Asset Management Ridgefield, Connecticut $147M AUM 25.76% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Brown, Lisle/Cummings's RMD Position: Q1 2026 in Review

Brown, Lisle/Cummings increased its ResMed (RMD) stake by 2.2% in Q1 2026, buying an estimated $1.5K and bringing the position to 276 shares worth $62K. The position accounts for 0.02% of the portfolio, ranked #325.

Brown, Lisle/Cummings first reported a position in RMD in Q4 2021 and has held it in 18 quarters since. The position peaked at $73.9K in Q3 2025. 941 funds tracked by Wall St. Rank hold RMD as of Q1 2026.

Brown, Lisle/Cummings held 276 shares of ResMed worth $62K as of Q1 2026.
Brown, Lisle/Cummings bought 6 ResMed shares in Q1 2026, an estimated $1.5K.
ResMed made up 0.02% of Brown, Lisle/Cummings's portfolio in Q1 2026, its #325 holding.
Brown, Lisle/Cummings first reported a position in ResMed in Q4 2021 and has held it in 18 quarters since.
Brown, Lisle/Cummings's ResMed position peaked at $73.9K in Q3 2025.
941 funds tracked by Wall St. Rank held ResMed as of Q1 2026.

Based on Brown, Lisle/Cummings's 13F filing for Q1 2026, filed 20 Apr 2026.